Table 2.
HCT Outcomes in 6 Dogs Given 5 mg/kg Anti-CD154 mAb 5c8 and Donor PBMCs before 1-Gy TBI Conditioning and DLA-Identical Marrow Grafts⁎
| Maximum Donor Chimerism (%) |
|||||||
|---|---|---|---|---|---|---|---|
| Dog ID No. | Nucleated Marrow Cells (× 108/kg) | Toxicities | Mononuclear Cells | Granulocytes | Cumulative CSP/MMF Dosing (% of Intended Dose) | Rejection (Week) | Outcome |
| G487 | 3.32 | GI† | 9.4 | 10.8 | 100/79 | Yes (22) | Alive, autologous recovery |
| G496 | 7.84 | GI, infection allergic reaction to mAb 5c8 | 71.0 | 82.8 | 100/64 | No | Alive, mixed chimerism |
| G521 | 8.08 | ∅ | 51.2 | 73.0 | 100/100 | No | Alive, mixed chimerism |
| G536 | 4.22 | GI | 24.5 | 33.9 | 100/75 | Yes (24) | Alive, autologous recovery |
| G577 | 2.26 | GI, intussusception | 10.2 | 28.9 | 89/79 | Yes (9) | Alive, autologous recovery |
| G579 | 3.59 | GI, allergic reaction to mAb 5c8 | 31.9 | 66.6 | 100/74 | No | Alive, mixed chimerism |
GI indicates gastrointestinal.
⁎
MMF + CSP were administered after grafting.
†
GI toxicities usually manifested as diarrhea, nausea, or anorexia.